Epigenetic Reprogramming Driven By Metabolic Alterations As A Mechanism Of EGFR – Tyrosine Kinase Inhibitor Resistance In Human Lung Adenocarcinoma

MLA

Xu Zhang, et al. “Epigenetic Reprogramming Driven By Metabolic Alterations As A Mechanism Of EGFR – Tyrosine Kinase Inhibitor Resistance In Human Lung Adenocarcinoma.” The FASEB Journal, vol. 34, Apr. 2020, p. 1. EBSCOhost, https://doi.org/10.1096/fasebj.2020.34.s1.00602.

APA

Xu Zhang, Tapan K Maity, Abhilash Venugopalan, Daniel R. Crooks, Vikram Misra, Nitin Roper, Andrew N. Lane, Andresson Thorkell, King C. Chan, W. Marston Linehan, Udayan Guha, Khoa Dang Nguyen, Constance M. Cultraro, Yue Qi, & Matthew Lynberg. (2020). Epigenetic Reprogramming Driven By Metabolic Alterations As A Mechanism Of EGFR – Tyrosine Kinase Inhibitor Resistance In Human Lung Adenocarcinoma. The FASEB Journal, 34, 1. https://doi.org/10.1096/fasebj.2020.34.s1.00602

Chicago

Xu Zhang, Tapan K Maity, Abhilash Venugopalan, Daniel R. Crooks, Vikram Misra, Nitin Roper, Andrew N. Lane, et al. 2020. “Epigenetic Reprogramming Driven By Metabolic Alterations As A Mechanism Of EGFR – Tyrosine Kinase Inhibitor Resistance In Human Lung Adenocarcinoma.” The FASEB Journal 34 (April): 1. doi:10.1096/fasebj.2020.34.s1.00602.